D. Wallwiener

19.9k total citations · 1 hit paper
608 papers, 12.8k citations indexed

About

D. Wallwiener is a scholar working on Oncology, Obstetrics and Gynecology and Cancer Research. According to data from OpenAlex, D. Wallwiener has authored 608 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 173 papers in Oncology, 122 papers in Obstetrics and Gynecology and 117 papers in Cancer Research. Recurrent topics in D. Wallwiener's work include Breast Cancer Treatment Studies (84 papers), Estrogen and related hormone effects (61 papers) and Cancer Cells and Metastasis (53 papers). D. Wallwiener is often cited by papers focused on Breast Cancer Treatment Studies (84 papers), Estrogen and related hormone effects (61 papers) and Cancer Cells and Metastasis (53 papers). D. Wallwiener collaborates with scholars based in Germany, United States and Switzerland. D. Wallwiener's co-authors include Tanja Fehm, Harald Seeger, Erich‐Franz Solomayer, Sara Y. Brucker, G. Bastert, Sven Becker, Erich Solomayer, Alfred O. Mueck, Karl Sotlar and Hans Neubauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

D. Wallwiener

570 papers receiving 12.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment

1998 627 citations Erich‐Franz Solomayer, D. Wallwiener et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Wallwiener Germany	54	5.0k	3.4k	2.5k	2.0k	1.9k	608	12.8k
Feng Gao United States	62	4.8k 0.9×	2.1k 0.6×	2.9k 1.2×	982 0.5×	2.2k 1.1×	473	13.4k
Christian Marth Austria	61	5.3k 1.0×	2.8k 0.8×	5.8k 2.4×	2.2k 1.1×	1.6k 0.8×	411	14.0k
Carolyn D. Runowicz United States	42	5.8k 1.2×	2.2k 0.7×	2.5k 1.0×	1.5k 0.7×	1.7k 0.9×	171	12.8k
Rainer Kimmig Germany	52	3.6k 0.7×	2.3k 0.7×	2.2k 0.9×	1.8k 0.9×	1.5k 0.8×	402	10.3k
Peter E. Schwartz United States	53	3.4k 0.7×	1.5k 0.4×	2.7k 1.1×	2.1k 1.0×	1.3k 0.7×	258	10.3k
Ulf‐Håkan Stenman Finland	70	4.1k 0.8×	2.4k 0.7×	5.5k 2.3×	1.4k 0.7×	2.9k 1.5×	608	20.1k
Hitoshi Tsuda Japan	73	7.9k 1.6×	5.7k 1.7×	7.2k 2.9×	1.4k 0.7×	2.4k 1.3×	610	20.2k
Robert P. Edwards United States	53	3.9k 0.8×	1.4k 0.4×	2.1k 0.9×	2.7k 1.4×	2.3k 1.2×	310	11.9k
W. Jonat Germany	48	4.7k 0.9×	3.7k 1.1×	2.0k 0.8×	693 0.3×	835 0.4×	298	9.8k
Hys Ngan Hong Kong	68	4.1k 0.8×	3.4k 1.0×	6.9k 2.8×	4.3k 2.2×	3.8k 2.0×	521	21.5k

Countries citing papers authored by D. Wallwiener

Since Specialization

Citations

This map shows the geographic impact of D. Wallwiener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Wallwiener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Wallwiener more than expected).

Fields of papers citing papers by D. Wallwiener

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Wallwiener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Wallwiener. The network helps show where D. Wallwiener may publish in the future.

Co-authorship network of co-authors of D. Wallwiener

This figure shows the co-authorship network connecting the top 25 collaborators of D. Wallwiener. A scholar is included among the top collaborators of D. Wallwiener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Wallwiener. D. Wallwiener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dannehl, Dominik, et al.. (2024). Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center. Archives of Gynecology and Obstetrics. 311(2). 437–442. 2 indexed citations

Neis, Felix, et al.. (2022). Proposal for a descriptive and differentiated presentation of the longitudinal impact of the new organized cancer screening guideline and HPV vaccination in Germany. Archives of Gynecology and Obstetrics. 307(4). 1125–1136. 3 indexed citations

Wenzel, Thomas J., Daniel A. Carvajal Berrio, Christl Reisenauer, et al.. (2020). Trans-Mucosal Efficacy of Non-Thermal Plasma Treatment on Cervical Cancer Tissue and Human Cervix Uteri by a Next Generation Electrosurgical Argon Plasma Device. Cancers. 12(2). 267–267. 26 indexed citations

Schroth, Werner, Florian Büttner, Siarhei Kandabarau, et al.. (2020). Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients. Clinical Cancer Research. 26(24). 6523–6534. 13 indexed citations

Rensburg, Ruan van, Ellen Honisch, Martina Rudelius, et al.. (2019). EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Molecular Cancer Research. 18(2). 278–286. 8 indexed citations

Wallwiener, Markus, Lina Maria Matthies, Elisabeth Simoes, et al.. (2017). Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. Journal of Medical Internet Research. 19(9). e322–e322. 41 indexed citations

Gluz, Oleg, C Liedtke, Jens Huober, et al.. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of Oncology. 27(6). 1035–1040. 10 indexed citations

Friedl, Thomas W. P., Fabienne Schochter, Christoph Scholz, et al.. (2015). Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Archives of Gynecology and Obstetrics. 293(2). 271–281. 40 indexed citations

Bareiss, Petra M., Anna Paczulla, Hui Wang, et al.. (2013). SOX2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma. Cancer Research. 73(17). 5544–5555. 126 indexed citations

10.

Bachmann, Cornelia, Eva‐Maria Grischke, Annette Staebler, Jens Schittenhelm, & D. Wallwiener. (2013). Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. Journal of Cancer Research and Clinical Oncology. 139(11). 1909–1916. 15 indexed citations

11.

Wallwiener, D.. (2012). Vorstellungen der DGGG zur wissenschaftlichen Weiterentwicklung und Struktur des Faches Gynäkologie und Geburtshilfe an den deutschen Universitäten. Geburtshilfe und Frauenheilkunde. 72(9). 2 indexed citations

12.

Bachmann, Cornelia, et al.. (2012). CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. Journal of Cancer Research and Clinical Oncology. 139(4). 551–556. 20 indexed citations

13.

Huebner, Markus, et al.. (2010). Pelvic floor muscle training for stress urinary incontinence: A randomized, controlled trial comparing different conservative therapies. Physiotherapy Research International. 16(3). 133–140. 46 indexed citations

14.

Krawczyk, Natalia, Małgorzata Banyś, Hans Neubauer, et al.. (2009). HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor.. PubMed. 29(10). 4019–24. 48 indexed citations

15.

Fehm, Tanja, Sven Becker, Karl Sotlar, et al.. (2007). Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Research. 9(5). R74–R74. 167 indexed citations

16.

Bonin, Michael, Susan E. Clare, Kay Nieselt, et al.. (2006). Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis. Cancer Research. 66(10). 5278–5286. 191 indexed citations

17.

Fehm, Tanja, W. Jäger, S. Kraemer, et al.. (2005). Changes of serum HER2 status during clinical course of metastatic breast cancer patients.. PubMed. 24(6). 4205–10. 16 indexed citations

18.

Kuehn, Thorsten, A. Bembenek, Thomas Decker, et al.. (2004). A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer. 103(3). 451–461. 92 indexed citations

19.

Rentzsch, Christine, et al.. (2004). A CD80-transfected human breast cancer cell variant induces HER-2/neu?specific T cells in HLA-A*02?matched situations in vitro as well as in vivo. Cancer Immunology Immunotherapy. 54(2). 129–140. 14 indexed citations

20.

Rentzsch, Christine, Simone Kayser, Steffen Walter, et al.. (2003). Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.. PubMed. 9(12). 4376–86. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact